Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced that a study on its flagship Gemini treatment showed the drug reduces inflammation in human blood cells. These results hold great promise for the treatment of conditions such as CKD (chronic kidney disease).
